INTERPARFUMS INC 10-Q

Item 1. Financial Statements In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our financial position, results of operations and cash flows for the interim periods presented. We have condensed such financial statements in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, such financial statements do not include all disclosures required by accounting principles generally accepted in the United States of America. In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the consolidated financial statements were issued by filing with the SEC. These financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2025 , included in our annual report filed on Form 10-K. The results of operations for the six months ended June 30, 2026 , are not necessarily indicative of the results to be expected for the entire fiscal year. Page 1 INTERPARFUMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands except share and per share data) (Unaudited) ASSETS June 30, 2026 December 31, 2025 Current assets: Cash and cash equivalents $ 169,704 $ 158,091 Short-term investments 41,642 137,093 Accounts receivable, net allowances of $ 8,412 and $ 7,224 , respectively 301,833 320,625 Inventories 375,584 351,377 Receivables, other 8,963 9,014 Other current assets 49,489 39,954 Income taxes receivable 3,755 11,211 Total current assets 950,970 1,027,365 Property, equipment and leasehold improvements, net 176,170 184,891 Right-of-use assets, net 20,685 23,347 Trademarks, licenses and other intangible assets, net 311,922 325,185 Deferred tax assets 9,848 4,234 Other assets 20,509 20,226 Total assets $ 1,490,104 $ 1,585,248 LIABILITIES AND EQUITY Current liabilities: Loans payable - banks $ 2,849 $ 9,400 Current portion of long-term debt 46,320 54,774 Current portion of lease liabilities 6,146 6,326 Accounts payable – trade 82,858 77,210 Accrued expenses 146,166 189,622 Income taxes payable 2,986 6,671 Total current liabilities 287,325 344,003 Long–term debt, less current portion 96,524 121,254 Lease liabilities, less current portion 13,075 15,967 Deferred tax liabilities 2,482 — Total liabilities $ 399,406 $ 481,224 Equity: Interparfums, Inc. shareholders’ equity: Preferred stock, $ .001 par; authorized 1,000,000 shares; none issued and outstanding — — Common stock, $ .001 par; authorized 100,000,000 shares; issued 41,104,625 and 41,100,125 and outstanding 32,025,781 and 32,067,285 shares at June 30, 2026 and December 31, 2025, respectively 32 32 Additional paid-in capital 127,652 127,541 Retained earnings 838,588 828,906 Accumulated other comprehensive loss ( 25,141 ) ( 9,029 ) Treasury stock, at cost, 9,078,844 and 9,032,840 shares at June 30, 2026 and December 31, 2025, respectively ( 70,670 ) ( 66,734 ) Total Interparfums, Inc. shareholders’ equity 870,461 880,716 Noncontrolling interest 220,237 223,308 Total equity 1,090,698 1,104,024 Total liabilities and equity $ 1,490,104 $ 1,585,248 See notes to condensed consolidated financial statements. Page 2 INTERPARFUMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands except per share data) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net sales $ 341,037 $ 333,936 $ 685,922 $ 672,755 Cost of sales 117,512 112,847 237,758 235,689 Gross margin 223,525 221,089 448,164 437,066 Selling, general and administrative expenses 174,584 161,913 325,089 302,813 Income from operations 48,941 59,176 123,075 134,253 Other expenses (income): Interest expense 1,457 1,787 2,891 3,332 Loss on foreign currency 67 1,580 169 2,360 Interest and investment (income) loss ( 690 ) 1,929 ( 3,008 ) 1,349 Other income ( 139 ) ( 245 ) ( 429 ) ( 324 ) Income before income taxes 48,246 54,125 123,452 127,536 Income taxes 11,364 12,928 29,867 30,936 Net income 36,882 41,197 93,585 96,600 Less: Net income attributable to the noncontrolling interests 6,395 9,209 19,732 22,120 Net income attributable to Interparfums, Inc. common shareholders $ 30,487 $ 31,988 $ 73,853 $ 74,480 Earnings per share: Net income attributable to Interparfums, Inc. common shareholders: Basic $ 0.95 $ 1.00 $ 2.31 $ 2.32 Diluted $ 0.95 $ 0.99 $ 2.31 $ 2.32 Weighted average number of shares outstanding: Basic 32,026 32,110 32,027 32,115 Diluted 32,026 32,149 32,027 32,162 Dividends declared per share $ 0.80 $ 0.80 $ 1.60 $ 1.60 See notes to condensed consolidated financial statements. Page 3 INTERPARFUMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In thousands) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Comprehensive income: Net income $ 36,882 $ 41,197 $ 93,585 $ 96,600 Other comprehensive income: Net derivative instrument gain (loss), net of tax ( 517 ) 2,172 ( 444 ) 6,505 Transfer from OCI into earnings 433 — ( 479 ) 1,631 Pension benefits, net of tax ( 53 ) ( 52 ) ( 108 ) ( 102 ) Foreign currency translation adjustments ( 4,823 ) 59,180 ( 21,983 ) 87,102 Comprehensive income 31,922 102,497 70,571 191,736 Comprehensive income attributable to the noncontrolling interests: Net income 6,395 9,209 19,732 22,120 Other comprehensive income: Net derivative instrument gain (loss), net of tax ( 23 ) 602 ( 3 ) 1,793 Pension benefits, net of tax ( 15 ) ( 15 ) ( 30 ) ( 29 ) Foreign currency translation adjustments ( 1,634 ) 15,458 ( 6,869 ) 22,732 Comprehensive income attributable to the noncontrolling interests 4,723 25,254 12,830 46,616 Comprehensive income attributable to Interparfums, Inc. $ 27,199 $ 77,243 $ 57,741 $ 145,120 See notes to condensed consolidated financial statements. Page 4 INTERPARFUMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (In thousands) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Common stock, beginning and end of period $ 32 $ 32 $ 32 $ 32 Additional paid-in capital, beginning of period 127,503 107,985 127,541 106,702 Shares issued upon exercise of stock options — 1,035 280 2,112 Share-based compensation 245 205 489 411 Other ( 96 ) — ( 658 ) — Purchase/Transfer of subsidiary shares — ( 423 ) — ( 423 ) Additional paid-in capital, end of period 127,652 108,802 127,652 108,802 Retained earnings, beginning of period 846,631 780,338 828,906 763,240 Net income 30,487 31,988 73,853 74,480 Dividends ( 25,622 ) ( 25,694 ) ( 51,263 ) ( 51,394 ) Reclassification Adjustment - See Note 1 ( 12,908 ) — ( 12,908 ) — Share-based compensation — 399 — 705 Retained earnings, end of period 838,588 787,031 838,588 787,031 Accumulated other comprehensive loss, beginning of period ( 21,853 ) ( 46,854 ) ( 9,029 ) ( 72,239 ) Foreign currency translation adjustment, net of tax ( 3,189 ) 43,722 ( 15,114 ) 64,370 Transfer from other comprehensive income into earnings 433 — ( 479 ) 1,631 Pension benefits, net of tax ( 38 ) ( 37 ) ( 78 ) ( 73 ) Net derivative instrument loss, net of tax ( 494 ) 1,570 ( 441 ) 4,712 Accumulated other comprehensive loss, end of period ( 25,141 ) ( 1,599 ) ( 25,141 ) ( 1,599 ) Treasury stock, beginning of period ( 70,670 ) ( 52,864 ) ( 66,734 ) ( 52,864 ) Shares repurchased — ( 2,043 ) ( 3,936 ) ( 2,043 ) Treasury stock, end of period ( 70,670 ) ( 54,907 ) ( 70,670 ) ( 54,907 ) Noncontrolling interest, beginning of period 230,909 218,882 223,308 197,774 Net income 6,395 9,209 19,732 22,120 Foreign currency translation adjustment, net of tax ( 1,634 ) 15,458 ( 6,869 ) 22,732 Pension benefits, net of tax ( 15 ) ( 15 ) ( 30 ) ( 29 ) Net derivative instrument gain, net of tax ( 23 ) 602 ( 3 ) 1,793 Share-based compensation 181 ( 177 ) 361 ( 122 ) Purchase of subsidiary shares from noncontrolling interests ( 248 ) — ( 1,496 ) — Other 96 — 658 — Reclassification Adjustment - See Note 1 12,908 — 12,908 — Dividends ( 28,332 ) ( 26,566 ) ( 28,332 ) ( 26,875 ) Noncontrolling interest, end of period 220,237 217,393 220,237 217,393 Total equity $ 1,090,698 $ 1,056,752 $ 1,090,698 $ 1,056,752 See notes to condensed consolidated financial statements. Page 5 INTERPARFUMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Six Months Ended June 30, 2026 2025 Cash flows from operating activities: Net income $ 93,585 $ 96,600 Adjustments to reconcile net income to net cash used in (provided by) operating activities: Depreciation and amortization 11,631 12,291 Provision for credit losses 537 108 Share-based compensation 850 946 Share of income of equity investment ( 436 ) ( 410 ) Noncash lease expense 3,045 3,969 Deferred tax provision ( 3,210 ) 5,821 Change in fair value of derivatives 933 ( 5,869 ) Changes in: Accounts receivable 10,700 3,637 Inventories ( 33,000 ) ( 16,802 ) Other assets ( 11,906 ) ( 5,631 ) Operating lease liabilities ( 3,206 ) ( 4,217 ) Accounts payable and accrued expenses ( 27,586 ) ( 74,044 ) Income taxes, net 3,730 ( 11,889 ) Net cash provided by operating activities 45,667 4,510 Cash flows from investing activities: Purchases of short-term investments ( 116,623 ) ( 47,361 ) Proceeds from sale of short-term investments 210,100 112,078 Purchases of property, equipment and leasehold improvements ( 2,389 ) ( 16,631 ) Payment for intangible assets acquired ( 2,736 ) ( 23,852 ) Net cash provided by investing activities 88,352 24,234 Cash flows from financing activities: Repayment of loans payable, bank ( 6,416 ) — Proceeds from loans payable, bank — 35,160 Proceeds from issuance of long-term debt — 54,635 Repayment of long-term debt ( 28,529 ) ( 23,795 ) Proceeds from exercise of options 280 2,112 Dividends paid ( 51,263 ) ( 51,394 ) Dividends paid to noncontrolling interest ( 28,332 ) ( 26,875 ) Other financing activities ( 479 ) — Purchase of subsidiary shares from noncontrolling interests ( 1,496 ) ( 408 ) Purchase of treasury stock ( 3,936 ) ( 2,043 ) Net cash used in financing activities ( 120,171 ) ( 12,608 ) Effect of exchange rate changes on cash ( 2,235 ) 9,885 Net increase in cash and cash equivalents 11,613 26,021 Cash and cash equivalents - beginning of period 158,091 125,433 Cash and cash equivalents - end of period $ 169,704 $ 151,454 Supplemental disclosure of cash flow information: Cash paid for: Interest $ 2,550 $ 3,031 Income taxes $ 25,385 $ 37,147 See notes to condensed consolidated financial statements. Page 6 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Significant Accounting Policies: The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ended December 31, 2026. The condensed consolidated balance sheet at December 31, 2025, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2025. Accounts Receivable Accounts receivables were $ 301.8 million, $ 320.6 million, $ 274.7 million as of June 30, 2026, December 31, 2025, and December 31, 2024, respectively. Inventories Inventories, including promotional merchandise, only include inventory considered saleable or usable in future periods, and are stated at the lower of cost and net realizable value, with cost being determined using an average cost method which approximates first-in, first-out (“FIFO”). Cost components include raw materials, direct labor and overhead (e.g., indirect labor, utilities, depreciation, purchasing, receiving, inspection and warehousing) as well as inbound freight. Promotional merchandise is charged to cost of sales at the time the merchandise is shipped to the Company’s customers. Income Taxes Our consolidated effective tax rate was 24.2 % and 24.3 % for the six months ended June 30, 2026 and 2025, respectively. The Company's effective income tax rate is primarily affected by the geographic mix of earnings among jurisdictions with different statutory tax rates, the benefit associated with the Foreign-Derived Intangible Income ("FDII") deduction, excess tax benefits related to stock-based compensation, state income taxes, and other permanent differences recognized during the period. These items collectively result in the Company's effective tax rate differing from the U.S. federal statutory rate. The company does not have a jurisdictional tax forecast but uses a forecasted tax rate by segment to validate the quarterly effective tax rate. Other than as discussed above, we did not experience any significant changes in tax rates, and none were expected in jurisdictions where we operate. We also did not have any material discreet tax items this quarter nor significant changes in uncertain tax positions, valuation allowances, tax examinations, or enacted law changes. The Company was notified in June 2026 by the Internal Revenue Service that the Company will undergo an audit for the 2024 tax year. Page 7 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements Correction of Immaterial Misstatements in Financial Statements Subsequent to the issuance of the December 31, 2025 consolidated financial statements, management identified a misclassification in the presentation of equity within the Consolidated Balance Sheets and Consolidated Statement of Changes in Shareholders’ Equity. Specifically, since inception, the equity component of Interparfums SA share-based compensation was improperly recorded in retained earnings rather than being presented in noncontrolling interest. The Company evaluated the misclassification under ASC 250, Accounting Changes and Error Corrections, considering both quantitative and qualitative factors, including SEC Staff Accounting Bulletin No. 99. Management concluded the misclassification was not material to the previously issued financial statements and recorded the $ 12.9 million reclassification correction in the current period. This adjustment is reflected in the Consolidated Balance Sheets and Statement of Changes in Shareholders’ Equity. Refer to the “Reclassification adjustment” line item in the Statement of Changes in Shareholders’ Equity. The revision affected only equity presentation in the Consolidated Balance Sheets and Statement of Changes in Shareholders’ Equity and had no impact on net income, operating income, cash flows, total assets, total liabilities, or total equity for any periods presented. Reclassifications Certain prior year amounts in the accompanying consolidated statement of cash flows and notes to consolidated financial statements have been reclassified to conform with current period presentation. 2. Recent Agreements: Nautica In January 2026, we entered into a 20 -year license agreement for Nautica brand fragrances and fragrance related products, a subsidiary of the Authentic Brands Group. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. Interparfums will assume full global responsibility for Nautica fragrances effective January 1, 2030. David Beckham In January 2026, we entered into a 20 -year license agreement for David Beckham brand fragrances and fragrance related products, a subsidiary of the Authentic Brands Group. This license will become effective on April 1, 2028. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. GUESS In 2018, GUESS?, Inc. and the Company signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the GUESS brand until December 31, 2033 . In December 2025, the license agreement was renewed for an additional 15 years, extending the license through December 31, 2048 . Page 8 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements Longchamp In July 2025, we announced that our 72 % owned French subsidiary, Interparfums SA, signed an exclusive license agreement with Longchamp, a Parisian Maison, through December 31, 2036 . Interparfums SA will be responsible for the creation, development, production and distribution of fragrance lines in Longchamp-brand points of sale and selective distribution channels. The first launch is expected in 2027. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. Annick Goutal In March 2025, we announced that our 72 % owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Goutal Paris held by Amorepacific Europe. In January 2026, Interparfums SA began commercial use of the fragrance brand. Coach In 2015, Coach and Interparfums SA signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the Coach brand until June 30, 2026. In March 2025, the license agreement was renewed for an additional 5 -year term, extending the license through June 30, 2031 . Abercrombie & Fitch and Hollister In March 2025, we expanded our Fierce distribution agreement, which now allows for a global distribution of the iconic Fierce fragrance line that either party may terminate on two year ’s notice. Furthermore, our existing Abercrombie & Fitch and Hollister fragrance license agreement will expire on March 14, 2028 . The goal of the updated Fierce distribution agreement is to drive, over time, more consistency between the products that are carried in the Abercrombie & Fitch stores and unaffiliated retailers. 3. Recent Accounting Pronouncements: In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. The ASU requires, among other things, more detailed disclosures about types of expenses in commonly presented expense captions such as cost of sales and selling, general and administrative expenses and is intended to improve the disclosures about an entity's expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization. ASU 2024-03 will also require the Company to disclose both the amount and the Company's definition of selling expenses. The guidance, as clarified by ASU 2025-01, is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our disclosures. In November 2025, the FASB issued ASU 2025 ‑ 09, Derivatives and Hedging (Topic 815): Hedge Accounting Improvements. The guidance makes targeted amendments to the hedge accounting model to better align the accounting with an entity’s risk management activities and to clarify the application of certain hedge accounting requirements. The amendments are effective for the Company for fiscal years beginning after December 15, 2026, including interim periods, with early adoption permitted. The Company is currently evaluating the impact of adopting this guidance on its hedge accounting policies and disclosures; however, the Company does not expect adoption to have a material impact on its consolidated financial position, results of operations, or cash flows. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”). This update clarifies the applicability, form and content, and interim disclosure requirements in ASC Topic 270 and enhances navigability of the interim reporting guidance. ASU 2025-11 also establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU 2025-11 will have on its interim consolidated financial statements. There are no other recent accounting pronouncements issued but not yet adopted that would have a material effect on our consolidated financial statements. Page 9 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements 4. Inventories: Inventories consist of the following: (in thousands): June 30, 2026 December 31, 2025 Raw materials and component parts $ 126,840 $ 129,706 Finished goods 248,744 221,671 $ 375,584 $ 351,377 5. Fair Value Measurement: The following tables present our financial assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value. Fair Value Measurements at June 30, 2026 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 41,642 $ 3,680 $ 37,962 $ — Interest rate swaps 1,651 — 1,651 — Total Assets $ 43,293 $ 3,680 $ 39,613 $ — Liabilities: Interest rate swaps $ 10 $ — $ 10 $ — Foreign currency forward exchange contracts not accounted for using hedge accounting 428 — 428 — Total Liabilities $ 438 $ — $ 438 $ — Fair Value Measurements at December 31, 2025 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 137,093 $ 3,801 $ 133,292 $ — Interest rate swaps 1,597 — 1,597 — Foreign currency forward exchange contracts not accounted for using hedge accounting 498 — 498 — Foreign currency forward exchange contracts accounted for using hedge accounting 169 — 169 — Total Assets $ 139,357 $ 3,801 $ 135,556 $ — Page 10 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements The carrying amount of cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued expenses approximate fair value due to the short terms to maturity of these instruments. The carrying amount of loans payable approximates fair value as the interest rates on the Company’s indebtedness approximate current market rates. The fair value of the Company’s long-term debt was estimated based on the current rates offered to companies for debt with the same remaining maturities and is approximately equal to its carrying value. Foreign currency forward exchange contracts are valued based on quotations from financial institutions and the value of interest rate swaps is the discounted net present value of the swaps using third party quotes from financial institutions. 6. Derivative Financial Instruments: The Company enters into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Before entering into a derivative transaction for hedging purposes, we determine that a high degree of initial effectiveness exists between the change in value of the hedged item and the change in the value of the derivative instrument from movement in exchange rates. High effectiveness means that the change in the cash flows of the derivative instrument will effectively offset the change in the cash flows of the hedged item. The effectiveness of each hedged item is measured throughout the hedged period and is based on the dollar offset methodology and excludes the portion of the fair value of the foreign currency forward exchange contract attributable to the change in spot-forward difference, which is reported in current period earnings. Any hedge ineffectiveness is also recognized as a gain or loss on foreign currency in the income statement. For contracts designated as hedges that are no longer deemed highly effective, hedge accounting is discontinued, and gains and losses accumulated in other comprehensive income are reclassified to earnings. If it is probable that the forecasted transaction will no longer occur, then any gains or losses accumulated in other comprehensive income are reclassified to current-period earnings. In December 2022, to finance the acquisition of the Lacoste trademark, the Company entered into a € 50 million (approximately $ 57.0 million) 4 -year term loan with a variable interest rate. This variable rate debt was swapped for variable interest rate debt with a maximum rate of 2 % per annum. This swap is a hedged derivative instrument and is therefore recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of comprehensive income. In connection with the April 2021 acquisition of the office building complex in Paris, € 120 million (approximately $ 136.7 million) of the purchase price was financed through a 10 -year variable rate term loan. The Company entered into interest rate swap contracts related to € 80 million of the loan, effectively exchanging the variable interest rate to a fixed rate of approximately 1.1 %. This derivative instrument is recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of income. Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in loss on foreign currency in the accompanying consolidated statements of income. Such gains and losses were immaterial for the six months ended June 30, 2026 and 2025 , respectively. All derivative instruments are reported as either assets or liabilities on the consolidated balance sheet measured at fair value. The fair value of interest rate swaps includes a liability position, which is included in long-term debt on the accompanying consolidated balance sheet, and an asset position, which is included in other current assets and other assets on the accompanying balance sheet. The fair value of foreign currency forward exchange contracts at June 30, 2026 , resulted in a net liability and is included in accrued expenses on the accompanying consolidated balance sheet. At June 30, 2026 , the Company had foreign currency contracts in the form of forward exchange contracts with notional amounts of approximately USD $ 52 million, all of which have maturities of less than one year . Page 11 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements 7. Commitments and Contingencies: Leases The Company leases its offices and warehouses, vehicles, and certain office equipment, substantially all of which are classified as operating leases. The Company currently has no material financing leases. The Company determines if an arrangement is a lease at inception. Operating lease assets and obligations are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining lease asset value, the Company considers fixed or variable payment terms, prepayments, incentives, and options to extend or terminate, depending on the lease. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company uses its incremental borrowing rate based on information available at the lease commencement date for the location in which the lease is held in determining the present value of lease payments. As of June 30, 2026 , the weighted average remaining lease term was 3.4 years and the weighted average discount rate used to determine the operating lease liability was 3.2 %. Rental expense related to operating leases was $ 1.5 million and $ 3.2 million for the three and six months ended June 30, 2026 , respectively, as compared to $ 1.7 million and $ 3.4 million for the corresponding periods of the prior year. Rental expense is included in selling, general and administrative expenses in the accompanying consolidated statements of income. Operating lease payments included in operating cash flows totaled $ 3.2 million and $ 4.2 million for the six months ended June 30, 2026 and 2025 , respectively, and noncash additions to operating lease assets totaled $ 0.5 million and $ 0.9 million for the six months ended June 30, 2026 and 2025 , respectively. IEEPA Tariffs On February 20, 2026, the U.S. Supreme Court ruled that certain tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”) by the executive branch are not lawful. On March 4, 2026, the Court of International Trade orders U.S. Customs and Border Protection to begin the refund process for all importers who were subject to IEEPA tariffs. The Company estimates it has paid approximately $ 17.6 million of IEEPA tariffs. As of June 30, 2026 , the Company has received $ 8.7 million of these refunds, and has received an additional $ 8.0 million in July 2026. The Company has elected to apply a gain contingency model in accordance with ASC 450-30, Gain Contingencies, to account for these recoveries, whereby a gain is recognized when the gain is realized, which occurs when the cash is received. The accounting for the IEEPA tariff refund reflects the original treatment of the underlying tariff costs. For the three and six months ended June 30, 2026 , the Company recognized $ 6.9 million for IEEPA tariffs associated with inventory that has been sold as a reduction in cost of sales in the Company’s Condensed Consolidated Statement of Income. For IEEPA tariffs associated with inventory on hand, the Company has reduced the carrying amount of inventory, which represented $ 1.8 million as of June 30, 2026 . Interest associated with IEEPA tariffs is recognized in interest and investment income in the Company’s Condensed Consolidated Statements of Income. Share Repurchase and Line of Credit In July 2026, the Board of Directors of our Company has authorized a share repurchase program to purchase outstanding shares in either our Company or its 72 % owned subsidiary, Interparfums SA, which has its shares traded on the Euronext under the symbol “ITP,” or both, and has authorized our Company to enter into a line of credit of up to the amount of $ 250 million to be repaid over a maximum of 6 years to fund the share repurchase program. The terms of the line of credit are still to be finalized. We cannot assure you that the entire repurchase program will be completed or that any minimum number of shares in our Company or Interparfums SA will be repurchased. Page 12 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements 8. Earnings per Share: Net income attributable to Interparfums, Inc. per common share (“basic EPS”) is computed by dividing net income attributable to Interparfums, Inc. by the weighted average number of shares outstanding. Net income attributable to Interparfums, Inc. per share assuming dilution (“diluted EPS”), is computed using the weighted average number of shares outstanding, plus the incremental shares outstanding assuming the exercise of dilutive stock options using the treasury stock method. The reconciliation between the numerators and denominators of the basic and diluted EPS computations is as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Numerator: Net income attributable to Interparfums, Inc. $ 30,487 $ 31,988 $ 73,853 $ 74,480 Denominator: Weighted average shares 32,026 32,110 32,027 32,115 Effect of dilutive securities: Stock options — 39 — 47 Denominator for diluted earnings per share 32,026 32,149 32,027 32,162 Earnings per share: Net income attributable to Interparfums, Inc. common shareholders: Basic $ 0.95 $ 1.00 $ 2.31 $ 2.32 Diluted $ 0.95 $ 0.99 $ 2.31 $ 2.32 Not included in the above computations are the effect of antidilutive potential common shares which consist of outstanding options to purchase 0.18 million shares of common stock for the three and six months ended June 30, 2026 and 0.08 million shares of common stock for the three and six months ended June 30, 2025 . 9. Accrued Expenses Accrued expenses consist of the following: June 30 , 2026 December 31 , 2025 Advertising liabilities $ 43,525 $ 71,463 Salary (including bonus and related taxes) 17,764 27,387 Royalties 30,470 29,343 Due vendors (not yet invoiced) 33,545 34,108 Retirement reserves 5,996 5,973 Refund (return) liability 4,560 12,166 Other 10,306 9,182 $ 146,166 $ 189,622 Page 13 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements 10. Revenue Recognition: Disaggregation of net sales by the Company’s geographic regions is as follows: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net sales by region.: North America $ 126,354 $ 122,400 $ 257,549 $ 245,413 Western Europe 83,687 89,837 170,178 176,040 Asia/Pacific 57,899 41,549 104,453 91,826 Central and South America 34,757 32,586 72,969 63,617 Eastern Europe 20,138 20,164 42,543 45,762 Middle East and Africa 18,202 27,400 38,230 50,097 $ 341,037 $ 333,936 $ 685,922 $ 672,755 Substantially all of our prestige fragrance brands are licensed from unaffiliated third parties, and our business is dependent upon the continuation and renewal of such licenses. With respect to the Company’s largest brands, we license the Coach, Jimmy Choo, Montblanc, GUESS, Lacoste, Donna Karan/DKNY, and Ferragamo brand names. As a percentage of net sales, product sales for the Company’s largest brands were as follows: Six Months Ended June 30, 2026 2025 Coach 19 % 17 % Jimmy Choo 18 % 17 % Montblanc 16 % 15 % GUESS 11 % 10 % Lacoste 7 % 8 % Donna Karan/DKNY 7 % 6 % Ferragamo 3 % 3 % For the six months ended June 30, 2026 , Macy's, our top retail customer, accounted for approximately 10 % of net sales. No one customer represented 10 % or more of net sales for the six months ended June 30, 2025. Page 14 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements 11. Segment Reporting: The Company manufactures and distributes one product line, fragrances and fragrance related products. The Company manages its business in two segments, European based operations and United States based operations. The European based operations, assets and business operations are primarily conducted in France, and include the results and assets of Interparfums Luxury Brands, Inc., located in the United States. For United States based operations, assets and business operations are primarily conducted in the United States, and include the results and assets of Interparfums Italia Srl, located in Italy. Both European based operations and United States based operations primarily represent the sale of prestige brand name fragrances. Information on the Company’s operations by segments is as follows: Three months ended June 30, 2026 Six months ended June 30, 2026 United States based operations European based operations Total United States based operations European based operations Total Net sales: $ 112,803 $ 231,090 $ 343,893 $ 208,939 $ 483,307 $ 692,246 Eliminations (a) ( 192 ) ( 2,664 ) ( 2,856 ) ( 192 ) ( 6,132 ) ( 6,324 ) 112,611 228,426 341,037 208,747 477,175 685,922 Less: (b) Cost of Sales 43,333 75,226 82,820 157,346 Eliminations (a) ( 95 ) ( 952 ) ( 95 ) ( 2,313 ) Segment gross margin 69,373 154,152 223,525 126,022 322,142 448,164 Less: (b) Advertising and Promotion 17,377 59,830 32,293 96,491 Employee Related costs 13,324 19,134 26,818 39,001 Royalties 9,316 21,558 17,770 45,010 Other segment items (c) 9,953 24,092 19,143 48,563 Segment income from operations $ 19,403 $ 29,538 $ 48,941 $ 29,998 $ 93,077 $ 123,075 Reconciliation: Interest Expense 1,457 2,891 Loss (gain) on foreign currency 67 169 Interest and investment income ( 690 ) ( 3,008 ) Other (income) expense ( 139 ) ( 429 ) Income before taxes $ 48,246 $ 123,452 Page 15 INTERPARFUMS, INC. AND SUBSIDIARIE Notes to Condensed Consolidated Financial Statements Three months ended June 30, 2025 Six months ended June 30, 2025 United States based operations European based operations Total United States based operations European based operations Total Net sales: $ 95,759 $ 240,549 $ 336,308 $ 190,104 $ 488,375 $ 678,479 Eliminations (a) — ( 2,372 ) ( 2,372 ) — ( 5,724 ) ( 5,724 ) 95,759 238,177 333,936 190,104 482,651 672,755 Less: (b) Cost of Sales 37,606 76,143 76,572 161,525 Eliminations (a) — ( 902 ) — ( 2,408 ) Segment gross margin 58,153 162,936 221,089 113,532 323,534 437,066 Less: (b) Advertising and Promotion 15,902 52,939 31,289 89,079 Employee Related costs 13,350 18,475 27,215 36,663 Royalties 7,235 20,470 14,273 41,493 Other segment items (c) 9,521 24,021 18,149 44,652 Segment income from operations $ 12,145 $ 47,031 $ 59,176 $ 22,606 $ 111,647 $ 134,253 Reconciliation: Interest Expense 1,787 3,332 Loss (gain) on foreign currency 1,580 2,360 Interest and investment income 1,929 1,349 Other (income) expense ( 245 ) ( 324 ) Income before taxes $ 54,125 $ 127,536 (a) Eliminations of intercompany sales relate to European based operations products sold to United States based operations. (b) The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker. (c) Other Segment items for each reportable segment include expenses for professional services, travel and entertainment, rent, warehousing, shipping, depreciation and amortization, and other selling, general and administrative costs. Page 16 INTERPARFUMS, INC. AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements Other segment disclosures: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net income attributable to Interparfums, Inc.: United States $ 15,457 $ 9,555 $ 23,879 $ 18,223 Europe 16,393 23,535 52,917 58,744 Eliminations ( 1,363 ) ( 1,102 ) ( 2,943 ) ( 2,487 ) $ 30,487 $ 31,988 $ 73,853 $ 74,480 Depreciation and amortization expense: United States $ 1,470 $ 1,753 $ 2,948 $ 3,433 Europe 4,362 4,611 8,683 8,858 $ 5,832 $ 6,364 $ 11,631 $ 12,291 Interest and investment income (loss): United States $ 593 $ 508 $ 958 $ 740 Europe 97 ( 2,437 ) 2,050 ( 2,089 ) $ 690 $ ( 1,929 ) $ 3,008 $ ( 1,349 ) Interest expense: United States $ 225 $ 394 $ 341 $ 604 Europe 1,232 1,393 2,550 2,728 $ 1,457 $ 1,787 $ 2,891 $ 3,332 Income tax expense: United States $ 4,054 $ 2,193 $ 6,125 $ 4,213 Europe 7,757 11,103 24,716 27,552 Eliminations ( 447 ) ( 368 ) ( 974 ) ( 829 ) $ 11,364 $ 12,928 $ 29,867 $ 30,936 Additions to long-lived assets(a): United States $ 561 $ 372 $ 1,969 $ 542 Europe 1,426 16,176 3,156 39,941 $ 1,987 $ 16,548 $ 5,125 $ 40,483 (a) Total long-lived assets include property, equipment and leasehold improvements, trademarks, licenses, and other intangible assets, and right-of-use assets. June 30, 2026 December 31, 2025 Total assets: United States $ 400,557 $ 369,871 Europe 1,106,175 1,229,174 Eliminations ( 16,628 ) ( 13,797 ) $ 1,490,104 $ 1,585,248 12. Subsequent Events: Management has evaluated subsequent events through the date the financial statements were available to be issued and determined that no subsequent events requiring disclosure have occurred except for those discussed in Note 7, including the IEEPA tariff refund received in July 2026 the board approval in July 2026 of the share repurchase program and line of credit. Page 17 INTERPARFUMS, INC. AND SUBSIDIARIES